AstraZeneca
AZN
519 hedge funds and large institutions have $13.9B invested in AstraZeneca in 2018 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 166 increasing their positions, 167 reducing their positions, and 40 closing their positions.
48% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 40
45% more call options, than puts
Call options by funds: $171M | Put options by funds: $118M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
3% more funds holding
Funds holding: 503 → 519 (+16)
4% more capital invested
Capital invested by funds: $13.4B → $13.9B (+$525M)
0.47% more ownership
Funds ownership: 15.21% → 15.68% (+0.47%)
1% less repeat investments, than reductions
Existing positions increased: 166 | Existing positions reduced: 167
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$192M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$87.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$79M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$68.6M |
| 5 |
YCMGA
York Capital Management Global Advisors
New York
|
+$56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$101M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$81.8M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$70.2M |
| 4 |
Dodge & Cox
San Francisco,
California
|
-$69.3M |
| 5 |
HP
Holowesko Partners
Nassau,
Bahamas
|
-$50.9M |
AZN Hedge Fund Activity: Q1 2018 in Review
519 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2018, worth a combined $13.9B — up 3.9% from $13.4B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new AZN positions and 40 closed out — a net gain of 19 holders — while 166 added to existing stakes and 167 trimmed.
The largest buyer was Primecap Management, adding an estimated $192M. The largest seller was Bank of America, cutting an estimated $101M.
- 519 institutional investors held AstraZeneca (AZN) as of Q1 2018, up from 503 in Q4 2017.
- Funds reported $13.9B of AstraZeneca stock for Q1 2018, up 3.9% quarter-over-quarter.
- 59 funds opened new AstraZeneca positions in Q1 2018 and 40 closed out, a net change of +19 holders.
- The largest AstraZeneca buyer in Q1 2018 was Primecap Management, an estimated $192M added.
- The largest AstraZeneca seller in Q1 2018 was Bank of America, an estimated $101M sold.
Based on aggregated 13F filings for Q1 2018.